<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853356</url>
  </required_header>
  <id_info>
    <org_study_id>13570-222</org_study_id>
    <nct_id>NCT03853356</nct_id>
  </id_info>
  <brief_title>Evidence For Fusion In Spine With Orthoss®</brief_title>
  <acronym>EFFISO</acronym>
  <official_title>Evidence For Fusion In Spine With Orthoss®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geistlich Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geistlich Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the performance and safety of the Orthoss® as a bone graft
      extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion rate</measure>
    <time_frame>6 months</time_frame>
    <description>Successful fusion should be based on the translational motion &lt; 3mm as well as on the angular motion &lt; 5° at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measure - Quality of Life: Oswestry Low Back Disability Index</measure>
    <time_frame>1-4 weeks; 3, 6, 12 and 24 months</time_frame>
    <description>Improvement in Oswestry Low Back Disability Index (ODI) of 15 or more at 24 months from the pre-operative value.Zero is equated with no disability and 100 is the maximum disability possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measure - Leg pain</measure>
    <time_frame>1-4 weeks, 3,6,12 and 24 months</time_frame>
    <description>Decrease in Visual Analog Scale for Pain (VAS) for leg by 3/10 or more at 24 months from the pre-operative value. Patients rated their leg pain intesity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score fo 10 representing &quot;pain as bad as it could be&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measure - Back pain</measure>
    <time_frame>1-</time_frame>
    <description>Decrease in Visual Analog Scale for Pain (VAS) for back by 3/10 or more at 24 months from the pre-operative value. Patients rated their back pain intesity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score fo 10 representing &quot;pain as bad as it could be&quot;.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Lumbar Spondylolisthesis Involving L4-L5</condition>
  <condition>Lumbar Spondylolisthesis Involving L5-S1</condition>
  <condition>Lumbar Spinal Stenosis</condition>
  <condition>Lumbar Disc Degeneration</condition>
  <arm_group>
    <arm_group_label>Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orthoss</intervention_name>
    <description>Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.</description>
    <arm_group_label>Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Orthoss® mixed with local bone and pedicle bone marrow aspirate in lumbar spondylodesis by
        using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion
        (PLIF) techniques in the 1-2 levels.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (male or female) must be 18 years or older

          -  The patient must be a candidate diagnosed with either degenerative disc disease
             including 1-2 level (L4-L5 and/or L5-S1) or dysplasic spondylolisthesis (degree 1 or
             2) or lumbar stenosis

          -  Previous low back surgery failure: foraminectomies and laminectomies

          -  If the patient is of child-bearing potential, the patient confirms not to be pregnant

          -  The patient is able to comply with the clinical investigation-related procedures such
             as attending all follow-up procedures

          -  The patient is able to fully understand the nature of the proposed surgery and is able
             to provide a signed informed consent including the use of the anonymized data for
             scientific publication

          -  The patient will not participate in another clinical investigation during this
             clinical investigation

        Exclusion Criteria:

          -  General contraindications for surgical treatment are present

          -  The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy
             within the past five years

          -  The patient is currently being treated with radiation, chemotherapy, immunosuppression
             or steroid therapy dose equivalent of more than 5mg prednisolon

          -  The patient is pregnant or nursing

          -  Women of childbearing age who are not using a highly effective method of birth control

          -  The patient has acute or chronic infection at the surgical site

          -  The patient has a known allergy to bovine bone material

          -  The patient has a medical history of alcohol or drug abuse within the last year prior
             to the screening examination

          -  Vulnerable population

          -  Patient is currently participating, or has participated in another clinical
             investigation within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Konieczny, MD</last_name>
      <phone>211 - 81 18314</phone>
      <phone_ext>+49</phone_ext>
      <email>Markus.Konieczny@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Markus Konieczny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Franke, MD</last_name>
      <phone>0391 791-5201</phone>
      <phone_ext>+49</phone_ext>
      <email>Joerg.Franke@Klinikum-Magdeburg.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Franke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar Technische Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehab Shiban, MD</last_name>
      <phone>089 / 4140 9715</phone>
      <phone_ext>+49</phone_ext>
      <email>ehab.shiban@tum.de</email>
    </contact>
    <investigator>
      <last_name>Ehab Shiban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

